Commercial Analytics Platform
Gain precision insights for improved commercial effectiveness
Platform · Cloud SaaSCompany source
Company profile
About IQVIA
IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company serves pharmaceutical manufacturers, biotech companies, medical device firms, payers, providers, and other healthcare stakeholders worldwide. IQVIA's comprehensive platform spans the entire product lifecycle, from early-phase clinical trials and regulatory compliance to commercialization and real-world evidence generation. The company leverages healthcare-grade AI, the world's largest healthcare data sets, and deep therapeutic expertise across multiple specialty areas including oncology, cardiovascular, rare diseases, cell and gene therapy, and many others. IQVIA's solutions include clinical trial design and execution, pharmacovigilance and safety monitoring, commercial analytics and HCP engagement, patient-centered technologies, and medical affairs support. With a global footprint spanning the Americas, Europe, Asia Pacific, and Middle East & Africa, IQVIA combines human expertise with cutting-edge technology to help clients navigate regulatory complexity, optimize clinical development, and maximize commercial performance. The company's integrated approach connects data, technology, and analytics to enable faster decision-making, reduce risk, and ultimately accelerate the delivery of life-changing therapies to patients.
Company description IQVIA official website
Mission. As a global community, IQVIA continuously invests and commits to advancing human health.
Primary marketClinical Trials & Research
Commercial modelCommercial information available on request
Work at IQVIA?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Allergy & Respiratory
- Biosimilars
- Cardiovascular
- Cell & Gene Therapy
- Central Nervous System
- Dermatology
- Endocrinology
- GI & Hepatology
- Infectious Diseases & Vaccines
- Nephrology
- Obesity
- Oncology & Hematology
- Ophthalmology
- Pediatrics
- Rare Diseases
- Reproductive Health
- Rheumatology
Who it serves
- Consumer Health
- Emerging Biopharma
- Financial Institutions
- Generics
- Government
- MedTech
- Patient Associations
- Payers
- Pharmaceutical Manufacturers
- Providers
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsArgentina · Australia & NZ · Belgium · Brazil · Bulgaria · Canada · Central America and Caribbean · China · Colombia · Czech Republic · Ecuador · France · Germany · Greece · Hungary · India · Ireland · Israel · Italy · Japan · Kazakhstan · Korea · Mexico · Middle East and Africa · Netherlands · Nordics · Poland · Romania · Russia · Slovakia · Southeast Asia · Spain · Sri Lanka · Switzerland · Turkey · Ukraine · United Kingdom · United States
Company sourceOfficial website
Company milestones
Platform expansion
Launched IQVIA Commercial Agentic AI to enhance precision and speed across commercial workflows; expanded patient engagement suite with integrated technology for clinical trials; advanced NLP platform for real-world evidence extraction
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Electronic Clinical Outcome Assessments (eCOA)
Capture high-quality patient data digitally
Software · Cloud SaaSCompany source
Health Data Apps & AI
Streamline research with the largest agnostic health data catalog
Platform · Cloud SaaSCompany source
Health Research Space
Enable secure, collaborative access to real-world data
Platform · Cloud SaaSCompany source
IQVIA AI
Healthcare-grade AI for life sciences and healthcare
Platform · Cloud SaaSCompany source
IQVIA Commercial Agentic AI
Enhance precision, speed, and business impact across commercial workflows
Platform · Cloud SaaSCompany source
Natural Language Processing Platform
Extract insights at scale from unstructured text
Platform · Cloud SaaSCompany source
Patient Engagement Suite
Connect with patients through integrated technology
Platform · Cloud SaaSCompany source
Patient Registries
Generate real-world insights by capturing patient outcomes
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Clinical, economic, and health-related quality of life impact of intrapartum group B Streptococcus (GBS) tests for prevention of neonatal GBS infection: a systematic literature review.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · Dec 1, 2026
Real-world outcomes in patients with advanced epithelial ovarian cancer receiving niraparib as first-line maintenance: a European retrospective cohort study.ESMO real world data and digital oncology · Dec 1, 2026
Real-world treatment patterns, healthcare resource utilization, and costs associated with high-risk endometrial cancer in England: a retrospective cohort study.Journal of medical economics · Dec 1, 2026
Incidence of comorbidities, healthcare resource utilization and costs among people with HIV.Journal of medical economics · Dec 1, 2026
Retrospective database analysis of annual direct costs and complications for patients with type 1 diabetes and hypoglycemia in the US.Journal of medical economics · Dec 1, 2026
Cost-effectiveness analysis of elranatamab versus physician's choice of treatment (non-BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan.Journal of medical economics · Dec 1, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Faster decision making
Clinical development optimization through AI and analytics
Reduced risk
Clinical trial execution and R&D strategy
Improved enrollment strategies
Patient engagement and site-centric solutions
Accelerated time to market
Launch excellence and regulatory compliance
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Seba Saad
Centralized Monitor
Eric Odongo
Senior Statistical Programmer
Mohamed Mostafa
Vice President & General Manager Strategic Partnerships and Growth Markets Middle East & Africa
Yuichi Yuda
Vice President of Corporate Strategy, PR,Business Development and Business Operations at IQVIA Japan
Abdessamad Charkaoui
Chief Financial Officer of Morocco
Gabriela Lerma Valencia
Commercial Engagement Services (CES) Latam Regional Leader
Bella Huang
Assistant General Counsel
Emilio Nicoli
Principal Enterprise Architect
06 · Company updates
Updates from IQVIA
Recent articles published on IQVIA's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
AI Models Achieve 85% Accuracy Predicting Clinical Trial Outcomes Before First Patient Enrolled
IQVIA's new predictive platform, powered by NVIDIA technology, promises to help drugmakers identify protocol flaws and optimize trial design through virtual simulation.
Drug Discovery & Research · Oct 13, 2026
When Anonymous Patient Data Isn't Anonymous: Italy's €7M Fine Exposes the Pseudonymization Trap in Healthcare AI
Italy's data regulator ruled that IQVIA's longitudinal database of one million patients was identifiable personal data, not anonymous information—challenging a core assumption underpinning real-world evidence collection for pharmaceutical research and AI training.
Policy & Regulation · Oct 4, 2026
IQVIA Promises to Slash Clinical Trial Startup Times by One-Third Using AI Platform
Healthcare giant unveils predictive development system claiming 33% faster study launches and 1.7x patient recruitment boost through automation and machine learning.
Drug Discovery & Research · Sep 8, 2026
How AI Slashed Diabetes Chart Reviews from 60,000 to 300 While Boosting Detection 127-Fold
IQVIA's award-winning clinical decision support tool demonstrates unprecedented efficiency gains in identifying adults misdiagnosed with type 1 diabetes, reducing clinician workload by 99.5% while dramatically improving diagnostic accuracy.
Clinical AI · Aug 22, 2026
The Validation Gap: Why AI-Designed Antibodies Just Hit Their First Real-World Reality Check
A landmark Nature Biotechnology benchmark reveals wildly inconsistent performance across 29 organizations' AI platforms, exposing the fragile evidence base beneath computational drug discovery's regulatory future.
Drug Discovery & Research · Aug 22, 2026
Eli Lilly Bets on Veeva's AI Agents to Power Global GLP-1 Commercial Blitz
As Lilly's revenue surges 48% on blockbuster obesity drugs, the pharma giant commits to deploying Veeva's \"agentic commercial\" AI framework worldwide to manage field engagement at unprecedented scale.
Healthcare Operations · Aug 17, 2026
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Clinical Trials & Research
Companies using AI to optimize clinical trial design, accelerate patient recruitment, match patients to trials, predict trial outcomes, or improve clinical research efficiency. Includes patient enrollment and screening platforms, AI-powered trial matching, and tools that reduce the time and cost of bringing new treatments to market.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.